Who founded Forcyte Biotechnologies?

Forcyte Biotechnologies was founded by Ivan Pushkarsky, Dino Di Carlo in 2017.

Who are Forcyte Biotechnologies's investors?

Forcyte Biotechnologies's investors include Sprint Vc, Y Combinator, Acequia Capital (AceCap).

How much funding has Forcyte Biotechnologies raised?

Forcyte Biotechnologies has disclosed $160K raised across 1 round.

Where is Forcyte Biotechnologies headquartered?

Forcyte Biotechnologies is headquartered in Los Angeles, US.

Forcyte Biotechnologies

DefunctYC W21

Los Angeles, US · Founded 2017 · Delaware corporation · 5 employees · 3 known investors

Find your way into Forcyte Biotechnologies

586 people in our graph share verified history with the Forcyte Biotechnologies team — schools, employers, funds. One of them is your warm intro.

Will Quistunlockedknows Dino Di Carlo · together at University of California, Berkeley (overlapped)

knows the team · via University of California, Davis

knows the team · via UCLA

×5knows the team · via University of California, Berkeley

×4knows the team · via Massachusetts General Hospital

Forcyte Biotechnologies develops drug screening tools that measure cell contractility to identify therapeutic candidates for diseases driven by abnormal cellular force generation, such as asthma, fibrosis, and hypertension.

Healthtech Medical Devices Drug discoveryUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W21)

Forcyte Biotechnologies was founded in 2017 by Ivan Pushkarsky and Dino Di Carlo.

Ivan Pushkarsky inCEO & Co-Founder2017–2026Dino Di Carlo. He has been involved in biotechnology development since 2013, with publications in peer-reviewed journals and experience securing SBIR grants and managing technology transfer.

Dino Di Carlo in 𝕏Co-Founder and Board Member2017–2026Dino Di Carlo is a professor of engineering and medicine at UCLA and holds an endowed chair position. He has co-founded multiple life science startups spanning research tools, diagnostics, medical devices, and pharmaceuticals, and holds over 50 patents in areas including microfluidics, nanosystems, and single-cell analysis.

Investors · 3

Sprint VcBangalore · $300

Y CombinatorSan Francisco · $500K

Acequia Capital (AceCap)reportedSeattle · $100K – $5M

Reported raises · per SEC filings

Form D private placements

$160K disclosed across 1 round · 2018

▶$160KraisedJan 2019 · 3 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Ivan PushkarskyExecutive Officer

Offering amount: $2M
Amount sold: $160K
Minimum investment: $25K
First sale: Dec 2018
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2021	$394.1K
National Institutes of Health (NIH)National Institutes of Health	Phase ISTTR	2021	$350K
National Institutes of Health (NIH)National Institutes of Health	Phase II	2019	$1.7M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2018	$288K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2018	$225K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2018	$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Forcyte Bio Secures New Funding From Y Combinator & Others, Bringing Total to >$5.7 Million - Forcyte Biotechnologies, Incforcytebio.com · Jun 2022

Forcyte Biotechnologies Secures Funding; Totals $5.7Mfinsmes.com · Jun 2022

Mechano-therapeutics Discovery Startup Forcyte Bio Secures New Funding From Y Combinator & Others, Bringing Total to >$5.7 Million, to Develop Drug Pipeline | Business Wirebusinesswire.com · Jun 2022

UPDATE: Brentwood-Based Forcyte Biotechnologies Targets $2M Raise - Los Angeles Business Journallabusinessjournal.com · Jan 2019

Forcyte Biotechnologies Funding | Complete Analysis | Extruct AIextruct.ai

Frequently asked questions

What does Forcyte Biotechnologies do?: Forcyte Biotechnologies develops drug screening tools that measure cell contractility to identify therapeutic candidates for diseases driven by abnormal cellular force generation, such as asthma, fibrosis, and hypertension.
Who founded Forcyte Biotechnologies?: Forcyte Biotechnologies was founded by Ivan Pushkarsky, Dino Di Carlo in 2017.
Who are Forcyte Biotechnologies's investors?: Forcyte Biotechnologies's investors include Sprint Vc, Y Combinator, Acequia Capital (AceCap).
How much funding has Forcyte Biotechnologies raised?: Forcyte Biotechnologies has disclosed $160K raised across 1 round.
Where is Forcyte Biotechnologies headquartered?: Forcyte Biotechnologies is headquartered in Los Angeles, US.